Methylation of FHIT gene promoter region in DNA from plasma of patients with myelodysplastic syndromes and demethylating effect of decitabine.
- Author:
Yin-Fen DENG
1
;
Lei ZHANG
;
Xiu-Qun ZHANG
;
Ming-Qiu HU
;
Dan DAI
;
Xue-Zhong ZHANG
;
Yan-Li XU
Author Information
1. Department of Hematology, Nanjing Medical University, Nanjing, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Acid Anhydride Hydrolases;
genetics;
Adult;
Aged;
Azacitidine;
analogs & derivatives;
therapeutic use;
DNA;
blood;
DNA Methylation;
Female;
Humans;
Male;
Middle Aged;
Myelodysplastic Syndromes;
blood;
drug therapy;
Neoplasm Proteins;
genetics;
Promoter Regions, Genetic
- From:
Journal of Experimental Hematology
2012;20(5):1144-1148
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to detect the methylation status of FHIT gene promoter region in the DNA from plasma of patients with myelodysplastic syndrome (MDS), and to investigate the demethylating effect of decitabine. Methylation-specific PCR method was used to detect the methylation status of FHIT gene promoter region in the DNA from plasma of 4 patients with MDS before and after treatment with decitabine plus semis CAG therapy (among them, 1 case of newly diagnosed MDS, 3 cases progressed into acute leukemia). The results indicated that 3 cases were found to have an increased methylation in the promoter region. After treatment with decitabine plus semis CAG, increased methylation was reversed in 2 cases. In 4 cases, 2 cases displayed clinical response. It is concluded that FHIT gene hypermethylation is associated with MDS pathogenesis. Decitabine has demethylating effect on the FHIT gene hypermethylation of plasma from MDS patients. Detecting the methylation status of FHIT gene in DNA from plasma may play a role in MDS auxiliary diagnosis or prognosis.
